Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 202333
Company: EPIC PHARMA LLC

Products on ANDA 202333

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
SODIUM POLYSTYRENE SULFONATE	SODIUM POLYSTYRENE SULFONATE	453.6GM/BOT	POWDER;ORAL, RECTAL	Prescription	AA	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 202333

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/19/2014	ORIG-1	Approval				Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
02/25/2020	SUPPL-1	Labeling-Package Insert		Label is not available on this site.

Therapeutic Equivalents for ANDA 202333

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL; 453.6GM/BOT
TE Code = AA

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
SODIUM POLYSTYRENE SULFONATE	SODIUM POLYSTYRENE SULFONATE	453.6GM/BOT	POWDER;ORAL, RECTAL	Prescription	No	AA	202333	EPIC PHARMA LLC
SODIUM POLYSTYRENE SULFONATE	SODIUM POLYSTYRENE SULFONATE	453.6GM/BOT	POWDER;ORAL, RECTAL	Prescription	No	AA	090313	UPSHER SMITH LABS